Select a city Select a city

Kamagra 100mg with pineapple 1 pack

#42106_761
 0 (0 review)
Characteristics
Status
Select a city
Find it at the pharmacyPharmacies
Brand country India
Quantity and shape1 პაკეტი
Genericssildenafil citrate
Short description
Indications: Kamagra Gel is prescribed for the treatment of erectile dysfunction in men.
7.73₾
1
Package
Select a city
To generate delivery methods
  • Description
  • Reviews

Composition
Each 5 g contains:
50 mg/100 mg sildenafil equivalent
Sildenafil gel

Clinical pharmacology
Mechanism of action
Kamagra jelly contains sildenafil citrate, a selective inhibitor of cyclic guanosine monophosphate (GMP) type 5 specific phosphodiesterase (PDE5). The physiological mechanism of penile erection involves the release of nitric oxide (NO) in the corpus cavernosum during sexual stimulation. NO then activates the enzyme guanylate cyclase, which leads to an increase in the level of cyclic guanosine monophosphate (cGMP), which in turn causes relaxation of smooth muscle in the corpus cavernosum and blood flow. Sildenafil citrate has no direct erectile effect on isolated human corpus cavernosum, but does not potentiate the action of nitric oxide by inhibiting phosphodiesterase type 5 (PDE5), which is responsible for cGMP degradation in the corpus cavernosum.
When sexual stimulation causes local release of NO, inhibition of PDE5 by sildenafil leads to an increase in cGMP levels in the corpus cavernosum. The result is relaxation of arterial smooth muscle and blood flow to the genitals, which leads to erection. Sildenafil citrate at recommended doses has no effect in the absence of sexual stimulation.
In vitro studies have shown that sildenafil citrate is selective for PDE5. It has a stronger effect on PDE5 than on other known phosphodiesterases (80-fold higher than on PDE1, 1000-fold higher than on PDE2, PDE3, PDE4). Importantly, the selectivity for PDE5 is 4000-fold higher than that for PDE3, since PDE is involved in the control of cardiac contractility, sildenafil citrate is approximately 10-fold more potent than PDE6, an enzyme found in the retina: such low selectivity is believed to be the main defect associated with color vision loss at relatively high doses and levels in plasma.

Pharmacokinetics
Kamagra Gel is rapidly absorbed from the oral cavity due to its rapid solubility. Bioavailability is 100% from plasma with a half-life of 4.73 hours. It is cleared primarily by CYP 3A4 (major route) and CYP 2C9 (minor route) liver microsomal isoenzymes. The drug is converted to the active metabolite by N-desmethylation and is then metabolized. This metabolite has a PDE-like profile similar to the parent drug and is 50% more effective at PDE5. Sildenafil is excreted mainly in the form of some metabolites and mainly in the feces (approximately 80% of the dose) and to a lesser extent in the urine (approximately 13% of the dose).
Indication
Kamagra Gel is prescribed for the treatment of erectile dysfunction in men.
Contraindications
Kamagra is contraindicated in patients with known hypersensitivity to the drug or any of its components. Due to the known effects of the drug on the nitrogen/Cyclopentyltransferase pathway, sildenafil citrate jelly has been shown to potentiate the hypotensive effects of nitrates and is contraindicated in patients concomitantly taking any form of organic nitrates.
Precautions
General
A detailed medical history and physical examination should be performed to diagnose erectile dysfunction, determine the potential underlying cause, and determine appropriate treatment.
There is a degree of cardiovascular risk associated with sexual activity. Therefore, it is advisable for the physician to perform a cardiovascular evaluation before initiating any treatment for erectile dysfunction.
Erectile dysfunction medications should be used with caution in patients with anatomical deformities of the penis (such as angular angulation, cavernosal fibrosis, Peyronie's disease) or in patients who may be predisposed to priapism (such as sickle cell anemia, multiple myeloma, or leukemia).
Pregnancy and the efficacy of Kamagra in combination with other treatments for erectile dysfunction have not been studied. Therefore, the use of such combinations is not recommended.
Kamagra Gel does not affect bleeding time when taken alone or with aspirin. In vitro studies on human platelets have shown that sildenafil potentiates the antiaggregatory effect of sodium nitroprusside (a nitric oxide donor). There is no information on the safety of Kamagra Jelly in patients with bleeding or active peptic ulcer disease. Therefore, Kamagra Gel should be used with caution in this group of patients.
Hereditary conditions - retinitis pigmentosa - a small number of patients have a genetically determined deficiency of retinal phosphodiesterase. There is no information on the safety of sildenafil citrate in patients with retinitis pigmentosa. Therefore, sildenafil citrate tablets should be used with caution in such patients.
Interaction with other medicinal products
Effect of other medicinal products on sildenafil
In vitro studies: Sildenafil metabolism occurs mainly with the participation of cytochrome CYP 3A4 (major pathway) and CYP 2C9 (minor pathway). Therefore, inhibitors of these isoenzymes may reduce sildenafil clearance.
In vivo studies: Cimetidine (80%), as a non-specific CYP inhibitor, caused a 56% increase in plasma sildenafil concentrations in healthy volunteers when co-administered with sildenafil (50 mg).
A more potent CYP3A4 inhibitor such as ketoconazole, itraconazole or mibefradil would be expected to have an even greater effect, and clinical data in patients have shown a decrease in sildenafil clearance when co-administered with CYP3A4 inhibitors (such as ketoconazole, erythromycin and cimetidine). Concomitant administration of CYP3A4 inducers such as rifampin is expected to reduce sildenafil plasma levels.
Single doses of antacids (magnesium hydroxide/aluminium hydroxide) did not affect the bioavailability of sildenafil.
Pharmacokinetic data from clinical studies in patients did not reveal any effect on the pharmacokinetics of sildenafil by CYP2C9 inhibitors (tolbutamide, warfarin type), CYP2D6 inhibitors (selective serotonin reuptake inhibitors, tricyclic antidepressants type), thiazide and related diuretics. ACE inhibitors and calcium channel blockers, the active metabolite of ACE, N-desmethylsildenafil, increased by 62% with potassium-sparing diuretics and by 102% with non-specific beta-blockers. This effect on the metabolite has no clinical consequences.
Effect of sildenafil on other medicinal products
In vitro studies: Sildenafil is a weak inhibitor of cytochrome P450 isoforms 1A2, 2C9, 2C19, 2D6, 2E1 and 3A4 (IC50>150 mM). Maximum plasma concentrations of sildenafil after administration of the recommended dose were approximately 1 mM, it is unlikely that sildenafil will alter the clearance of substrates of these isoenzymes.
In vivo studies: No interactions were observed with tolbutamide (250 mg) or warfarin (40 mg), which are metabolized by CYP2C9.
Sildenafil (50 mg) did not accelerate the increase in bleeding time caused by aspirin (150 mg).
Sildenafil (50 mg) did not potentiate the hypotensive effect of alcohol in healthy volunteers with a maximum blood alcohol level of 0.08%.
No interaction was observed when sildenafil (100 mg) was administered with amlodipine in hypertensive patients. The mean additional reduction in supine blood pressure (systolic 8 mmHg; diastolic - 7 mmHg) was the same as that observed when sildenafil was administered alone to healthy volunteers.
Analysis of the safety database did not reveal any differences in the adverse event profile between patients receiving sildenafil with or without antihypertensive treatment.
Women
Sildenafil is not prescribed for women
Pregnancy
There are no adequate and well-controlled studies of sildenafil in pregnant women. Sildenafil is not prescribed for pregnant women.
Lactation
Sildenafil is not prescribed for breastfeeding women.
Pediatric treatment
Sildenafil is not prescribed for children
Side effects
Sildenafil citrate has been prescribed to more than 3700 patients (aged 19-87 years) worldwide in clinical trials. More than 550 – were treated for a period of more than one year. According to placebo-controlled clinical trials, discontinuation of the drug due to adverse reactions with sildenafil citrate (2.5%) did not significantly exceed the figures for various forms of placebo. (2.3%). Adverse reactions are usually transient, mild or moderate in nature.
In the case of oral jelly, adverse reactions are similar to those observed with other dosage forms.
When sildenafil was studied in placebo-controlled clinical trials with flexible recommended dosing (on an as-needed basis), with side effects occurring in more than 2% of patients (more often with sildenafil than with placebo), headache, flushing, dyspepsia were reported in more than 2% of patients (more often with sildenafil than with placebo). Nasal congestion, urinary tract infection, diarrhea, dizziness, rash and visual impairment (moderate and transient, especially changes in color vision, as well as increased sensitivity to light and blurred vision).
Other adverse reactions occurring in more than 2% of patients, but as often as with placebo, were: respiratory tract infection, back pain, flu-like syndrome and arthralgia.
In a fixed-dose study, dyspepsia (17%) and blurred vision (11%) were more common with the 100 mg dose than with the lower doses. At the above doses, the recommended dose level, adverse reactions were similar to those listed above but were reported more or less frequently overall.
In controlled clinical trials, the following adverse reactions occurred in <2% of patients; a causal relationship to sildenafil has not been established. Adverse reactions reported include those with a proven relationship to drug use; minor adverse reactions have been excluded.
Body as a Whole: Facial edema, photosensitivity, shock, weakness, pain, chills, accidental fall, abdominal pain, allergic reactions, chest pain, accidental trauma.
Cardiovascular system: angina pectoris, atrioventricular block, migraine, fainting, tachycardia, increased heart rate, decreased blood pressure, postural hypotension, myocardial ischemia, cerebral thrombosis, cardiac arrest, heart failure, abnormal electrocardiogram, cardiomyopathy.
Digestive system: nausea, glossitis, colitis, dysphagia, gastritis, gastroenteritis, esophagitis, stomatitis, dry mouth, liver dysfunction, rectal bleeding, gingivitis.
Blood and lymphatic system: anemia and leukopenia
Metabolic and nutritional system: thirst, edema, gout, unstable diabetes, hyperglycemia, peripheral edema, hyperuricemia, hypoglycemic reaction, hypernatremia.
Musculoskeletal system: arthritis, arthrosis, myalgia, tendon rupture, tenosynovitis, bone pain, myasthenia, synovitis.
Nervous system: ataxia, hypertonia, neuralgia, neuropathy, paresthesia, tremor, dizziness, depression, insomnia, drowsiness, unusual thinking, decreased reflexes and hypoesthesia.
Respiratory system: asthma, shortness of breath, laryngitis, pharyngitis, sinusitis, bronchitis, increased salivation, increased cough.
Skin and skin appendages: urticaria, herpes simplex, pruritus, sweating, skin ulceration, contact dermatitis.
Special sensations: mydriasis, conjunctivitis, photophobia, tinnitus, eye pain, deafness, earache, intraocular hemorrhage, cataract, dry eye.
Urinary system: cystitis, nocturia, frequent urination, gynecomastia, urinary retention, abnormal ejaculation, swelling of the genitals and anorgasmia.
Dosage and administration
The main group of patients is prescribed Kamagra-gel - 50 mg half an hour before sexual intercourse. The maximum recommended dose is 100 mg, administered only once a day.
The following factors are associated with an increase in plasma sildenafil levels: age over 65 years (40% increase in AUC), hepatic insufficiency (e.g. cirrhosis, 80%), severe renal insufficiency (creatinine clearance < 100 mg), as higher plasma levels may increase both efficacy and side effects, patients should be monitored regularly and the use of the 100 mg oral gel is contraindicated in these patients.
Overdose
In studies conducted in healthy volunteers receiving 800 mg of the drug, adverse reactions were similar to those observed with lower doses, although their frequency increased.
In case of overdose, standard maintenance therapy should be implemented as needed. Increased clearance by renal dialysis is not expected. Sildenafil is tightly bound to plasma proteins and is not excreted in the urine.
Shelf life
3 years from the date of manufacture. The drug should not be used after the expiration date.
Form of release
Kamagra gel 50 mg/100 mg, in 5 g sachets.
Storage conditions
Store in a cool, dry place, protected from light.
Warning
Keep out of reach of children
Manufacturer
Ajanta Pharma Limited
Ajanta House, Charkop, Kandivli (3)
Mumbai 400 067
Made in India.

Translated by AI